Study of MGTA-145 and Plerixafor in Patients With Sickle Cell Disease
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This research study is designed to investigate a new potential medicine for mobilizing stem
cells and apheresis collection in patients with Sickle Cell Disease. MGTA-145, the new
potential medicine, will be given with plerixafor.